AlphaStreet Newsdesk powered by AlphaStreet Intelligence
Kiniksa Pharmaceuticals International, plc reported first-quarter results that exceeded Wall Street expectations, with the biopharmaceutical company posting diluted earnings of $0.27 per share against a consensus estimate of $0.21, a beat of 28.6%. Revenue totaled $214.3M for the quarter, up 56.0% from $137.8M in the year-ago period. Net income reached $22.6M as the company continued expanding its commercial footprint across the United States, the United Kingdom, and international markets.
The quarter’s performance was driven entirely by ARCALYST, which generated $214.3M in revenue, representing 56.0% growth year-over-year. The therapy’s momentum was supported by an expanding prescriber base, with 4,550 prescribers having written ARCALYST prescriptions at quarter end. Earnings per share of $0.27 marked a substantial acceleration from $0.11 a year ago, representing a 145.4% increase.
Management expects full-year ARCALYST net product revenue of $930.0M to $945.0M. The performance comes as Kiniksa works to establish its position in the competitive biopharmaceutical landscape, where developing and commercializing medical therapies requires sustained investment and clinical validation. Wall Street maintains a positive stance on the stock, with analyst consensus standing at 8 buy ratings, 1 hold, and 0 sell recommendations.
A detailed analysis of Kiniksa Pharmaceuticals International, plc’s quarter follows shortly on AlphaStreet.
This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.